STOCK TITAN

Clarivate Plc - CLVT STOCK NEWS

Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.

Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.

Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.

Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.

Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.

The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.

Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.

For more information about Clarivate, its products, and services, visit www.clarivate.com.

Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has acquired Patient Connect, enhancing its patient engagement capabilities. This acquisition enables Clarivate to deliver advanced clinical messaging to physicians and pharmacists, improving patient outcomes. Patient Connect reaches 834,000 physicians and 600,000 pharmacists globally, serving over 1 billion patients. Clarivate aims to leverage Patient Connect’s solutions to provide comprehensive, real-world data insights across Europe, the US, Asia-Pacific, and Latin America, thereby accelerating healthcare innovation and supporting life sciences organizations in informed decision-making.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) collaborated with KAIST Innovation Strategy and Policy Institute to release a report analyzing the global AI innovation landscape. The report highlights AI's transformative role across industries and emphasizes the importance of quality over quantity in innovation. Key insights reveal that neural networks and machine learning have experienced over 46% growth since 2010, with the U.S. leading in influential AI inventions. The findings suggest that national strategies play a crucial role in developing successful AI ecosystems, impacting future capabilities and economic growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) released its annual report identifying key biopharmaceutical trends of 2021. Major highlights include the ongoing impact of COVID-19 on the industry, breakthroughs in Alzheimer's treatments, and the emergence of DNA vaccines.

Despite the pandemic, R&D investments surged, achieving record financing levels. Innovations in artificial intelligence were also noteworthy, with Australia recognizing AI as a patent inventor. The report underscores the resilience of the biopharmaceutical sector in continuing advancements despite external challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT), in collaboration with the Chinese Academy of Engineering and Higher Education Press, has released the Engineering Fronts 2021 report, identifying 93 engineering research fronts and 93 development fronts across nine fields, including mechanical, chemical, and information engineering. The report highlights 28 key engineering research and development areas crucial for future innovation. Jeremy Lawson from Clarivate emphasized the importance of this report in guiding global engineering research, while CAE's Zhong Zhihua acknowledged its role in shaping academic direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (CLVT) and the Chinese Academy of Sciences released the "Research Fronts 2021" report, identifying 171 research fronts, including 110 hot and 61 emerging areas across sciences and social sciences. Notably, a third of these fronts relate to COVID-19, highlighting their critical role in combating the pandemic. This marks the eighth consecutive year of collaboration between Clarivate and CAS, showcasing their commitment to enhancing research insights. The report also indicates that the US leads in research performance, closely followed by China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has released a report titled Luxury brands: Re-calibrating brand strategies for a changing world, highlighting how luxury brands are evolving in response to market challenges. The report indicates that luxury brands are venturing into sectors like software and gaming, with LVMH showing significant trademark activity in these areas. Furthermore, it predicts that by 2025, half of luxury purchases will come from Gen Z and millennials, who are increasingly engaged in digital platforms. The report also warns of rising risks in brand protection within the digital sphere.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has released a report highlighting the potential of telehealth to address healthcare disparities among Black Americans. The report emphasizes the need for equitable access to telehealth services, especially following the COVID-19 pandemic, which exposed significant gaps in healthcare accessibility. Challenges such as reimbursement structures and technology barriers hinder progress. Recommendations include enhancing reimbursement policies, investing in broadband infrastructure, and improving provider training in telehealth practices. The report aims to inform stakeholders on actionable strategies to improve healthcare equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
none
-
Rhea-AI Summary

Dana Incorporated (NYSE: DAN) has appointed Timothy R. Kraus as its new senior vice president and chief financial officer, succeeding Jonathan Collins, who will join Clarivate plc (NYSE: CLVT). Kraus, a Dana veteran with over a decade at the company, previously served as senior vice president of finance and treasurer, overseeing global treasury operations and strategic acquisitions. CEO James Kamsickas acknowledged Kraus's crucial role in Dana's transformation strategy, enhancing innovation and balance sheet strength. Collins will assist in the transition until December 15, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
none
-
Rhea-AI Summary

Clarivate (NYSE: CLVT) announced a leadership change with the departure of CFO Richard Hanks, effective December 16, 2021. His successor, Jonathan Collins, currently CFO of Dana (NYSE: DAN), will take over to drive the company's ongoing growth. Hanks will assist during the transition until April 1. Collins brings extensive experience from Dana and ProQuest, where he held senior financial roles. Clarivate's Executive Chairman praised Hanks for his contributions over the past five years and expressed confidence in Collins' ability to lead the financial strategy moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
none
Rhea-AI Summary

Clarivate has successfully completed its acquisition of ProQuest for $5.3 billion, enhancing its position as a global leader in information and analytics. This acquisition, announced on May 17, 2021, adds ProQuest's software, content, and analytics capabilities to Clarivate's portfolio. The combined entity now boasts over 11,000 employees serving 45,000 customers worldwide. The integration aims to unlock synergies and offer enriched services to research-focused organizations, while maintaining investment in existing product lines. Key leadership changes include Jonathan Collins as the new CFO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags

FAQ

What is the current stock price of Clarivate Plc (CLVT)?

The current stock price of Clarivate Plc (CLVT) is $4.98 as of December 20, 2024.

What is the market cap of Clarivate Plc (CLVT)?

The market cap of Clarivate Plc (CLVT) is approximately 3.5B.

What does Clarivate do?

Clarivate provides transformative intelligence, offering enriched data, insights, and analytics across sectors like Academia & Government, Intellectual Property, and Life Sciences & Healthcare.

What are some of Clarivate’s trusted brands?

Some of Clarivate’s most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™.

Where is Clarivate headquartered?

Clarivate is headquartered in London and operates in over 100 countries.

How did Clarivate become an independent company?

Clarivate was formerly part of Thomson Reuters and became an independent company in 2016 after being sold to private equity.

When did Clarivate go public?

Clarivate went public on the New York Stock Exchange in 2019.

What recent advancements has Clarivate made in the field of cancer treatment?

Clarivate has been exploring the rapid pipeline growth and clinical trials in CAR T-cell therapies, particularly in China, as part of their commitment to innovative cancer treatments.

What is Cortellis CMC Intelligence™?

Cortellis CMC Intelligence™ is a solution that helps pharmaceutical, biotech, and generics companies streamline regulatory tracking and optimize lifecycle management for small molecules and biologics.

What is Epidemiology Intelligence™?

Epidemiology Intelligence™ combines epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics.

What is the purpose of the Trademark Watch Analyzer?

The Trademark Watch Analyzer is an AI-enhanced trademark protection solution that provides faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

How does Clarivate enhance patient outcomes with HealthWise Data?

Clarivate's partnership with HealthWise Data integrates Social Determinants of Health (SDoH) attributes into its Real-World Data repository, offering nuanced patient insights to enhance outcomes and healthcare equity.

Clarivate Plc

NYSE:CLVT

CLVT Rankings

CLVT Stock Data

3.54B
389.32M
15.85%
92.75%
5.06%
Information Technology Services
Services-computer Processing & Data Preparation
Link
United States of America
ST. HELIER